Table 4 |
|||||||
|
Summary of grade 3 and 4 laboratory and hematologic toxicities |
|||||||
|
Parameter |
Grade |
Placebo (n = 13) |
Belimumab |
||||
|
|
|||||||
|
1.0 mg/kg (n = 15) |
4.0 mg/kg (n = 14) |
10 mg/kg (n = 14) |
20 mg/kg (n = 14) |
All active (n = 57) |
|||
|
|
|||||||
|
Activated partial thromboplastin time |
3 |
0 |
0 |
1 (7) |
0 |
1 (7) |
2 (4) |
|
Creatinine |
3 |
0 |
0 |
0 |
0 |
1 (7)a |
1 (2) |
|
Hemoglobin |
3 |
0 |
1 (7) |
0 |
0 |
0 |
1 (2) |
|
Hyperglycemia |
3 |
0 |
1 (7) |
0 |
0 |
1 (2) |
|
|
Neutropenia |
3 |
0 |
0 |
1 (7)b |
2 (14) |
0 |
3 (5) |
|
Thrombocytopenia |
4 |
0 |
0 |
1 (7)b |
0 |
0 |
1 (2) |
|
Proteinuria |
3 |
0 |
0 |
0 |
1 (7) |
1 (7)a |
2 (4) |
|
4 |
0 |
0 |
0 |
0 |
1 (7) |
1 (2) |
|
|
Prothrombin time |
3 |
3 (23)c |
1 (7)c |
0 |
0 |
0 |
1 (2) |
|
4 |
2 (15)c |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
Values are expressed as n (%). aOne patient had grade 3 serum creatinine and grade 3 proteinuria. bOne patient with grade 3 neutropenia and grade 4 thrombocytopenia after the first 10-mg/kg dose was rechallenged at grade 1 neutropenia, without further decline after the second dose. cFour of six patients with grade 3 or 4 prothrombin time reported concomitant warfarin use, including the two patients with grade 4 prothrombin time. |
|||||||
|
Furie et al. Arthritis Research & Therapy 2008 10:R109 doi:10.1186/ar2506 |
|||||||